Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and ADME Study of Zamicastat in Healthy Men
NCT04069130Phase 1Completed
- Sponsor
- BIAL
- Start
- Jan 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zamicastat in pulmonary arterial hypertension (PAH) and heart failure (HF), sponsored by BIAL. Primary endpoints: Amount excreted at Day 15, Cumulative amount excreted at Day 15 and 13 more. Started Jan 2019; status: completed.
02
Drugs
zamicastat
03
Conditions
pulmonary arterial hypertension (PAH)heart failure (HF)
Beyond the preview
Go deeper on NCT04069130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04069130.